Preemptive azacitidine treatment guided by measurable residual disease (MRD) status was associated with delayed relapse in patients with myelodysplastic neoplasms or acute myeloid leukemia (AML), with ...
Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics ...
The BD OneFlow™ AML/MDS Panel is intended for qualitative flow-cytometric immunophenotyping of mature and immature hematopoietic cells populations (lymphoid and myeloid lineages) in bone marrow and ...
Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MFSOUTH SAN FRANCISCO, Calif., March 30, ...
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdin ...
TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results